Evidence map›Paper›PMID 41685208›Full record

ArticleFrontiers in molecular biosciences2025

Qunfeng Huang, Dongheng Yang, Zhu Tao, Zhaoqing Yu, Wenting Ding, Na Tao, Xiulin Liao, Haoxin Lin, Zhipeng Cheng, Susu Gao and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. The theory of tumor immuno-ecodynamics.Frontiers in immunology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Qunfeng Huang *Guangdong Engineering Technology Research Center for Biological Targeting Diagnosis, Therapy, and Rehabilitation, Department of Oncology, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Dongheng Yang *Guangdong Engineering Technology Research Center for Biological Targeting Diagnosis, Therapy, and Rehabilitation, Department of Oncology, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Zhu Tao *CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd., Guangzhou, China.
Zhaoqing Yu *Guangdong Engineering Technology Research Center for Biological Targeting Diagnosis, Therapy, and Rehabilitation, Department of Oncology, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Wenting DingCAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd., Guangzhou, China.
Na TaoGuangdong Engineering Technology Research Center for Biological Targeting Diagnosis, Therapy, and Rehabilitation, Department of Oncology, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Xiulin LiaoSchool of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, China.
Haoxin LinGuangdong Engineering Technology Research Center for Biological Targeting Diagnosis, Therapy, and Rehabilitation, Department of Oncology, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Zhipeng ChengCAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd., Guangzhou, China.
Susu GaoCAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd., Guangzhou, China.
Zhongkui KangCAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd., Guangzhou, China.
Jianming XieCAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd., Guangzhou, China.
Wen HuCAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd., Guangzhou, China.
Li QinGuangdong Engineering Technology Research Center for Biological Targeting Diagnosis, Therapy, and Rehabilitation, Department of Oncology, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Xiaoping ChenCAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd., Guangzhou, China.
Guifang YuGuangdong Engineering Technology Research Center for Biological Targeting Diagnosis, Therapy, and Rehabilitation, Department of Oncology, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: We established a subcutaneous Lewis lung cancer model in C57BL/6J mice and treated them with intraperitoneal injection of Results: Conclusion: Based on our past and current studies, we can draw the following conclusion:

Indexed as

high-dimensional flow cytometryimmune profilesimmunotherapynon-small cell lung cancerPlasmodium infectiontumor ecosystem

Identifiers

PMID41685208
PMCPMC12892102

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.